September 6, 2018 / 6:09 AM / a year ago

Roche says FDA extends review period for Tecentriq by three months

ZURICH, Sept 6 (Reuters) - Swiss drugmaker Roche said on Thursday it was notified by the U.S. Food and Drug Administration (FDA) that the review period for Tecentriq (atezolizumab) to treat a form of lung cancer had been extended by three months to allow the FDA to review additional information.

The FDA is expected to make a decision on the approval by Dec. 05, Roche said. (Reporting by Silke Koltrowitz; Editing by Maria Sheahan)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below